BR112016028567A2 - método para utilizar ligante anti-fgf23 e para tratar doença e/ou condição relacionada com fgf23 e para aumentar a remodelação óssea - Google Patents
método para utilizar ligante anti-fgf23 e para tratar doença e/ou condição relacionada com fgf23 e para aumentar a remodelação ósseaInfo
- Publication number
- BR112016028567A2 BR112016028567A2 BR112016028567A BR112016028567A BR112016028567A2 BR 112016028567 A2 BR112016028567 A2 BR 112016028567A2 BR 112016028567 A BR112016028567 A BR 112016028567A BR 112016028567 A BR112016028567 A BR 112016028567A BR 112016028567 A2 BR112016028567 A2 BR 112016028567A2
- Authority
- BR
- Brazil
- Prior art keywords
- fgf23
- treating
- condition
- related disease
- bone remodeling
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000010072 bone remodeling Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 208000029663 Hypophosphatemia Diseases 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003553 hypophosphatemic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001132—Fibroblast growth factors [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR122023023102-3A BR122023023102A2 (pt) | 2014-06-09 | 2015-05-29 | Uso de um anticorpo anti-fgf23 para o tratamento de um distúrbio hipofosfamético associado a níveis e/ou atividade anormais do fator de crescimento de fibroblastos 23 (fgf23) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462009474P | 2014-06-09 | 2014-06-09 | |
PCT/US2015/033226 WO2015191312A1 (en) | 2014-06-09 | 2015-05-29 | The effective and efficient control of serum phosphate for optimal bone formation |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016028567A2 true BR112016028567A2 (pt) | 2018-01-30 |
Family
ID=54769049
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR122023023102-3A BR122023023102A2 (pt) | 2014-06-09 | 2015-05-29 | Uso de um anticorpo anti-fgf23 para o tratamento de um distúrbio hipofosfamético associado a níveis e/ou atividade anormais do fator de crescimento de fibroblastos 23 (fgf23) |
BR112016028567A BR112016028567A2 (pt) | 2014-06-09 | 2015-05-29 | método para utilizar ligante anti-fgf23 e para tratar doença e/ou condição relacionada com fgf23 e para aumentar a remodelação óssea |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR122023023102-3A BR122023023102A2 (pt) | 2014-06-09 | 2015-05-29 | Uso de um anticorpo anti-fgf23 para o tratamento de um distúrbio hipofosfamético associado a níveis e/ou atividade anormais do fator de crescimento de fibroblastos 23 (fgf23) |
Country Status (23)
Country | Link |
---|---|
US (4) | US10639360B2 (pt) |
EP (2) | EP3151859B1 (pt) |
JP (2) | JP6808493B2 (pt) |
KR (2) | KR20210099180A (pt) |
CN (1) | CN106604743A (pt) |
AR (1) | AR100689A1 (pt) |
AU (1) | AU2015275128C1 (pt) |
BR (2) | BR122023023102A2 (pt) |
CA (1) | CA2949234C (pt) |
CL (1) | CL2016003179A1 (pt) |
CY (1) | CY1124328T1 (pt) |
DK (1) | DK3151859T3 (pt) |
ES (1) | ES2851674T3 (pt) |
HR (1) | HRP20210250T1 (pt) |
HU (1) | HUE053271T2 (pt) |
LT (1) | LT3151859T (pt) |
MX (2) | MX2016016296A (pt) |
PE (1) | PE20170248A1 (pt) |
PL (1) | PL3151859T3 (pt) |
PT (1) | PT3151859T (pt) |
RS (1) | RS61443B1 (pt) |
SI (1) | SI3151859T1 (pt) |
WO (1) | WO2015191312A1 (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE039448T2 (hu) | 2004-04-21 | 2018-12-28 | Alexion Pharma Inc | Csontba szállító konjugátumok és alkalmazási módszerük a fehérjék csontba juttatására |
PL3151859T3 (pl) | 2014-06-09 | 2021-07-26 | Ultragenyx Pharmaceutical Inc. | Efektywna i skuteczna kontrola stężenia fosforanów w surowicy dla optymalnego tworzenia kości |
WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
JP6787894B2 (ja) | 2014-12-05 | 2020-11-18 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 組換えアルカリホスファターゼを用いた発作の処置 |
AU2016211447B2 (en) | 2015-01-28 | 2021-09-23 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
KR102644116B1 (ko) | 2015-08-17 | 2024-03-05 | 알렉시온 파마슈티칼스, 인코포레이티드 | 알칼린 포스파타제의 제조 |
JP6868617B2 (ja) | 2015-09-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ(tnsalp)酵素補充療法に有効な投薬計画の特定 |
JP2018533571A (ja) | 2015-10-30 | 2018-11-15 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 患者の頭蓋縫合早期癒合症を治療するための方法 |
WO2017155569A1 (en) | 2016-03-08 | 2017-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
US10898549B2 (en) | 2016-04-01 | 2021-01-26 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
WO2017173413A1 (en) | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Treating muscle weakness with alkaline phosphatases |
WO2017214130A1 (en) | 2016-06-06 | 2017-12-14 | Alexion Pharmaceuticals, Inc. | Metal impact on manufacturing of alkaline phosphatases |
WO2018035420A1 (en) | 2016-08-18 | 2018-02-22 | Alexion Pharmaceuticals, Inc. | Methods for treating tracheobronchomalacia |
CN106709662B (zh) * | 2016-12-30 | 2021-07-02 | 山东鲁能软件技术有限公司 | 一种电力设备运行工况划分方法 |
CN110719786A (zh) | 2017-03-31 | 2020-01-21 | 阿雷克森制药公司 | 用于治疗成人和青少年的低磷酸酯酶症(hpp)的方法 |
JP2021519590A (ja) | 2018-03-30 | 2021-08-12 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 糖タンパク質の製造 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
AU2005202100A1 (en) | 1999-05-11 | 2005-06-09 | Ortho-Mcneil Pharmaceutical, Inc. | Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
IL151928A0 (en) | 2000-03-30 | 2003-04-10 | Whitehead Biomedical Inst | Rna sequence-specific mediators of rna interference |
KR20090036151A (ko) | 2000-07-19 | 2009-04-13 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코포레이션 | 신규 섬유아세포 성장 인자 (fgf23) 및 그의 이용 방법 |
CN100387713C (zh) | 2000-08-11 | 2008-05-14 | 麒麟医药株式会社 | 调节磷酸代谢,钙代谢,钙化和维生素d代谢的多肽及其编码dna |
ATE378403T1 (de) | 2000-11-30 | 2007-11-15 | Medarex Inc | Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern |
ATE441666T1 (de) | 2001-12-28 | 2009-09-15 | Kyowa Hakko Kirin Co Ltd | Antikírper gegen den fibroblastenwachstumsfaktor 23 |
US8158725B2 (en) | 2005-08-22 | 2012-04-17 | Bridgestone Corporation | Functionalized polymers and tires therefrom |
US7883705B2 (en) | 2007-02-14 | 2011-02-08 | Kyowa Hakko Kirin Co., Ltd. | Anti FGF23 antibody and a pharmaceutical composition comprising the same |
US8889621B2 (en) | 2009-10-30 | 2014-11-18 | New York University | Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia |
WO2012050673A1 (en) | 2010-10-14 | 2012-04-19 | Wisconsin Alumni Research Foundation | Methods for the treatment of x-linked hypophosphatemia and related disorders |
PL3151859T3 (pl) | 2014-06-09 | 2021-07-26 | Ultragenyx Pharmaceutical Inc. | Efektywna i skuteczna kontrola stężenia fosforanów w surowicy dla optymalnego tworzenia kości |
-
2015
- 2015-05-29 PL PL15806501T patent/PL3151859T3/pl unknown
- 2015-05-29 HU HUE15806501A patent/HUE053271T2/hu unknown
- 2015-05-29 DK DK15806501.1T patent/DK3151859T3/da active
- 2015-05-29 MX MX2016016296A patent/MX2016016296A/es unknown
- 2015-05-29 CA CA2949234A patent/CA2949234C/en active Active
- 2015-05-29 RS RS20210173A patent/RS61443B1/sr unknown
- 2015-05-29 CN CN201580039280.XA patent/CN106604743A/zh active Pending
- 2015-05-29 PT PT158065011T patent/PT3151859T/pt unknown
- 2015-05-29 JP JP2016569651A patent/JP6808493B2/ja active Active
- 2015-05-29 AU AU2015275128A patent/AU2015275128C1/en active Active
- 2015-05-29 EP EP15806501.1A patent/EP3151859B1/en active Active
- 2015-05-29 PE PE2016002698A patent/PE20170248A1/es unknown
- 2015-05-29 ES ES15806501T patent/ES2851674T3/es active Active
- 2015-05-29 KR KR1020217024284A patent/KR20210099180A/ko not_active IP Right Cessation
- 2015-05-29 SI SI201531522T patent/SI3151859T1/sl unknown
- 2015-05-29 BR BR122023023102-3A patent/BR122023023102A2/pt unknown
- 2015-05-29 AR ARP150101715A patent/AR100689A1/es unknown
- 2015-05-29 WO PCT/US2015/033226 patent/WO2015191312A1/en active Application Filing
- 2015-05-29 US US14/725,320 patent/US10639360B2/en active Active
- 2015-05-29 BR BR112016028567A patent/BR112016028567A2/pt not_active Application Discontinuation
- 2015-05-29 LT LTEP15806501.1T patent/LT3151859T/lt unknown
- 2015-05-29 KR KR1020177000293A patent/KR20170013993A/ko not_active Application Discontinuation
- 2015-05-29 EP EP20208220.2A patent/EP3845245A1/en active Pending
-
2016
- 2016-12-08 MX MX2021003740A patent/MX2021003740A/es unknown
- 2016-12-09 CL CL2016003179A patent/CL2016003179A1/es unknown
-
2020
- 2020-03-26 US US16/831,179 patent/US11202822B2/en active Active
- 2020-12-09 JP JP2020204298A patent/JP6993490B2/ja active Active
-
2021
- 2021-02-12 HR HRP20210250TT patent/HRP20210250T1/hr unknown
- 2021-02-23 CY CY20211100154T patent/CY1124328T1/el unknown
- 2021-11-12 US US17/525,738 patent/US11771748B2/en active Active
-
2023
- 2023-08-07 US US18/366,447 patent/US20240115683A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016028567A2 (pt) | método para utilizar ligante anti-fgf23 e para tratar doença e/ou condição relacionada com fgf23 e para aumentar a remodelação óssea | |
BR112017021021A2 (pt) | inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer | |
BR112017011972A2 (pt) | derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais | |
PE20191251A1 (es) | Moleculas de fijacion para el tratamiento del cancer | |
MX2018000465A (es) | Derivados de diaril y arilheteroaril urea como moduladores del receptor de serotonina 5-ht2a útiles para la profilaxis y el tratamiento de alucinaciones asociadas con una enfermedad neurodegenerativa. | |
BR112017027951A2 (pt) | composto inibitório de brk | |
CR20150217A (es) | Inhibidores de histona demetilasas | |
BR112016015706A8 (pt) | composto, uso do mesmo e composição farmacêutica | |
PE20150887A1 (es) | Compuestos de benceno sustituidos | |
BR112016003201A2 (pt) | inibidores de grp94 seletivos e usos dos mesmos | |
BR112017015864A2 (pt) | compostos e métodos para modular a expressão de tmprss6 | |
BR112016014481A2 (pt) | tratamento de câncer utilizando combinações de inibidores de erk e raf | |
BR112015009168A2 (pt) | composto de fórmula estrutural xi, uso de um composto, composição farmacêutica, método de tratamento de uma doença mediada pela pde4 em um sujeito, método de modulação de uma função mediada pela pde4 em um sujeito, método de alcançar um efeito em um paciente e método para inibir a pde4 | |
BR112015021999A2 (pt) | inibidores de indoleamina 2,3-dioxigenase (ido) | |
BR112016022742A2 (pt) | composições e métodos para modular a expressão de receptor de hormônio do crescimento | |
BR112017004741A2 (pt) | compostos e composições como inibidores da raf quinase | |
BR112017018092A2 (pt) | composto, composição farmacêutica, e, método para tratar e/ou prevenir uma doença ou distúrbio. | |
BR112017003346A2 (pt) | derivados de pirazolopiridina, seus usos, e composição farmacêutica | |
BR112017006705A2 (pt) | inibidores de biossíntese de sulfato de heparan para o tratamento de doenças | |
BR112016021648A2 (pt) | novos compostos | |
BR112016022593A2 (pt) | composições e métodos para modular a expressão do fator b do complemento | |
BR112017010440A2 (pt) | administração sublingual de riluzol | |
BR112017009552A8 (pt) | Métodos para alvejar o controle transcricional em regiões de super-realçador | |
BR112017026535A2 (pt) | composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto | |
BR112017003433A2 (pt) | inibidores espirocíclicos de catepsina c |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: ULTRAGENYX PHARMACEUTICAL INC. (US) ; KYOWA KIRIN CO., LTD. (JP) |
|
B25G | Requested change of headquarter approved |
Owner name: ULTRAGENYX PHARMACEUTICAL INC. (US) ; KYOWA KIRIN CO., LTD. (JP) |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122023023102-3 PROTOCOLO 870230097473 EM 03/11/2023 20:45. |